ClinicalTrials.gg
Not yet recruitingNCT07792382EXPOUpdated Oct 30, 2026

Executive Function Play Opportunities for Children With Down Syndrome

An interventional study of EXPO and EXPO Extended in Down Syndrome and Trisomy 21, sponsored by Colorado State University. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 36 Months to 72 Months. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Colorado State University · Not applicable, Interventional, and Treatment

Updated Oct 30, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
36 Months to 72 Months
Sex
All
01

Study summary

The Executive Function Play Opportunities (EXPO) study is a sequential, multiple assignment, randomized trial (SMART) evaluating adaptive caregiver-mediated intervention pathways for improving executive function (EF) in children with Down syndrome (DS). At baseline, participants will be randomized in a 1:4 ratio to receive either a delayed-treatment control condition or the EXPO intervention. After 4 weeks of standard EXPO intervention in stage 1, participants in the EXPO condition will be assessed for response to the intervention based on prespecified criteria for improvement in laboratory-based EF performance. Early responders will continue with the standard EXPO intervention in stage 2. Slower responders will be randomized to either the EXPO Extended or EXPO Foundations pathway. All participants will complete laboratory and parent-report measures of EF immediately post-intervention and 3 months later. Participants in the delayed-treatment control condition will complete the same assessments as the EXPO groups and will be offered the EXPO intervention after completion of the 3-month follow-up.

Read the detailed description

The Executive Function Play Opportunities (EXPO) study is a sequential, multiple assignment, randomized trial (SMART) evaluating adaptive caregiver-mediated intervention pathways for improving executive function (EF) in children with Down syndrome (DS). At baseline, all participants will complete an assessment including laboratory-based measures of EF, parent-report measures of EF, and intensive ecological measurement of EF using the iBehavior app. Participants will then be randomized in a 1:4 ratio to receive either a delayed-treatment control condition or the EXPO intervention, with a target total sample size of 150.

During stage 1, participants in the EXPO condition will complete 4 weeks of standard EXPO intervention. The initial weeks of EXPO consist of 2 weeks of EXPO Ready activities followed by 2 weeks of Working Memory activities, and all participants in the EXPO intervention receive ongoing support from an EXPO coach.

At the stage 1 evaluation, conducted 4 weeks after starting EXPO, all participants will complete the laboratory-based EF assessment battery. EXPO participants will be assessed for response to the intervention and classified as early or slower responders based on prespecified criteria for improvement in laboratory-based EF performance.

Early responders will be assigned to the standard EXPO intervention in stage 2 and continue with activities targeting inhibition, cognitive flexibility, planning, and consolidation of skills for a total of 12 weeks. Slower responders will be randomly assigned in a 1:1 ratio to either the EXPO Extended or EXPO Foundations pathway. The EXPO Extended pathway will include the same core activities as the EXPO standard pathway but will provide additional intervention time, for a total of 18 weeks. The EXPO Foundations pathway will begin with a block of activities targeting early social communication and regulation to provide a foundation for activity engagement, followed by more foundational versions of activities targeting inhibition and cognitive flexibility. The EXPO Foundations pathway will continue for a total of 12 weeks.

All participants will complete laboratory and parent-report measures of EF immediately post-intervention and 3 months later. Participants in the delayed-treatment control condition will not receive EXPO during the initial study period but will complete the same assessments as participants in the EXPO intervention. Following completion of the 3-month follow-up, participants in the delayed-treatment control condition will be offered the EXPO intervention.

02

Conditions studied

  • Down Syndrome
  • Trisomy 21

Browse trials for

Keywords

  • executive function
  • parent-implemented
  • play based
  • preschooler
  • early childhood
  • developmental
03

In context

Down Syndrome

438 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

This study's planned enrollment of 150 is above the median of 37 across 286 interventional studies indexed under Down Syndrome.

Browse Down Syndrome studies →

Lead sponsor

Colorado State University is the lead sponsor of 117 studies on the registry; 19 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
36 Months to 72 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed medical diagnosis of Down syndrome

Exclusion criteria

Exclusion Criteria:

  • no complete hearing or vision loss
  • primary exposure to English or Italian
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • No intervention
    Delayed-Treatment Control

    Participants do not receive EXPO during the initial study period and complete the same EF assessments as participants in the EXPO intervention pathways. Participants are offered the EXPO intervention following completion of the 3-month follow-up.

  • Experimental
    EXPO Standard Pathway

    Early responders to EXPO at the stage 1 evaluation are assigned to the standard, 12 -week intervention with activities refined from EXPO 2.0.

    Behavioral: EXPO

  • Active comparator
    Adaptive Pathway 1/EXPO Extended

    Half of participants classified as slower responders to EXPO at the stage 1 evaluation are randomly assigned to EXPO Extended. EXPO Extended provides the standard pathway activities with an extended 18-week schedule.

    Behavioral: EXPO Extended

  • Active comparator
    Adaptive Pathway 2/EXPO Foundations

    Half of participants classified as slower responders to EXPO at the stage 1 evaluation are randomly assigned to EXPO Foundations. EXPO Foundations provides a more foundational pathway with simplified activities, and additional activities that emphasize early communication and regulatory processes.

    Behavioral: EXPO Foundations

Interventions

  • BehavioralEXPO

    EXPO is a novel intervention that targets the development of EF through play-based opportunities for children with DS and their primary caregivers. EXPO is a 'syndrome-informed' intervention in that all activities are tailored to phenotypic strengths and challenges associated with DS, accounting for cognitive, language, and motor presentations frequently observed in this population. EXPO is also designed to elicit maximal engagement and enjoyment for children and their caregivers by embedding opportunities to strengthen EF component processes in the context of play and games.

    Also known as: Executive Function Play Opportunities

  • BehavioralEXPO Extended

    Alternative EXPO pathway that extends the length of the EXPO intervention from 12 to 18 weeks to provide more time and opportunity for skill acquisition.

  • BehavioralEXPO Foundations

    An augmented version of EXPO that places a greater emphasis on precursors to EXPO activity engagement, including an increased number of social routine activities, enhanced presses for social communication behaviors like joint attention, enhanced focus on early self-regulation skills, and adaptations of all EXPO activities in each block that emphasize more foundational aspects of play.

06

What researchers measure

Primary outcomes

  1. Adapted Reverse Categorization

    Rule switch task that involves sorting by color, and then reversing the sort rule. Scores are calculated as the number of items correctly sorted after reversing the sort rule; scores range from 0 to 10 and a higher score indicates a better outcome.

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

  2. Zoo Animal Switch

    Rule switch task that involves sorting large and small animal pairs by size into large and small buckets, then reversing the rule to put large animals into the small bucket, and small animals into the large bucket. Scores are calculated as the number of items correctly sorted after reversing the sort rule; scores range from 0 to 10 and a higher score indicates a better outcome.

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

  3. Developmental Profiles-4 Cognitive domain

    Growth Scale Values in the Developmental Profiles-4 Cognitive domain. Growth scale values (GSV) are vertically scaled scores designed to track real skill gains over time; scores range from approximately 300 to 800 and a higher score indicates a better outcome.

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

  4. Developmental Profiles-4 Social-emotional domain

    Growth Scale Values in the Developemental Profiles-4 Social-Emotional domain. Growth scale values (GSV) are vertically scaled scores designed to track real skill gains over time; scores range from approximately 400 to 600 and a higher score indicates a better outcome.

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

Secondary outcomes

  1. iBehavior Ecological Momentary Assessment

    This daily report will be completed in week-long bursts by families. Families respond to a 29-item questionnaire that asks about daily use of executive function skills. A lower score indicates a better outcome.

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

  2. Self ordered pointing: Garage Game

    Self-ordered pointing task that requires working memory/updating

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

  3. BRIEF-Preschool Inhibition Domain

    Standardized Caregiver Report of Executive Functioning for Preschool aged children

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

  4. Hearts and Flowers

    Opposites task that involves matching cards to the opposite type of card

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

  5. Developmental Profiles-4 Adaptive Behavior domain

    Growth Scale Values in the Developmental Profiles-4 Adaptive Behavior domain

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

  6. Building Task

    Shape design task that involves reproducing a pattern of blocks according to a design produced by the examiner

    Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — Upon completion of this study, and annually throughout the three-year project period, our team will share all developmental and behavioral data with the NIH INCLUDE Data Coordinating Center (DCC). Data will also be collected from a parent or guardian via questionnaire and the iBehavior smartphone application. Data that will be preserved and shared include demographic information, developmental assessments composite scores, caregiver rating composite scores for behavioral dimensions, and caregiver-reported iBehavior composite data. The data transformation approach for all aggregate-level data will be specified in detail in a protocol manual for reproducibility. Information regarding data content, format, and organization will be available to any research colleagues accessing the DCC database. All shared data will be formatted in accordance with current standards and norms in the field.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Nov 30, 2029

Access criteria: Data will be made available within the National Institutes of Health (NIH) INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Data Coordinating Center (DCC) system, allowing researchers to access it in accordance with their approved access level. All data and secondary analyses will be included in the DCC. The DCC will use its current policies and procedures for access by interested research teams.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 163 non-industry interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 35. This study's planned 36 months is above that.

Counting every sponsor, half of 165 studies reached it within 11 months; a quarter within 3 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Sep 2026 → Dec 2026, primary completion Aug 2029 → Dec 2029 and completion Nov 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Aug 28, 2026
StartEst.
Dec 1, 2026was Sep 2026
Primary completionEst.
Dec 31, 2029was Aug 2029
CompletionEst.
Jan 10, 2030was Nov 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Dec 1, 2026
Oct 30, 2026
Primary completion
Aug 31, 2029→Dec 31, 2029
Oct 30, 2026
Study completion
Nov 30, 2029→Jan 10, 2030
Oct 30, 2026
Primary outcomes
4 time frame changed, 4 description edited
What changed in the outcomes
  • Time frameAdapted Reverse CategorizationFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • Time frameZoo Animal SwitchFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • Time frameDevelopmental Profiles-4 Cognitive domainFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • Time frameDevelopmental Profiles-4 Social-emotional domainFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • DescriptionAdapted Reverse Categorization: how it is measured was reworded
  • DescriptionDevelopmental Profiles-4 Cognitive domain: how it is measured was reworded
  • DescriptionDevelopmental Profiles-4 Social-emotional domain: how it is measured was reworded
  • DescriptionZoo Animal Switch: how it is measured was reworded
Oct 30, 2026
Secondary outcomes
6 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameiBehavior Ecological Momentary AssessmentFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • Time frameSelf ordered pointing: Garage GameFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • Time frameBRIEF-Preschool Inhibition DomainFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • Time frameHearts and FlowersFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • Time frameDevelopmental Profiles-4 Adaptive Behavior domainFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • Time frameBuilding TaskFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
  • DescriptioniBehavior Ecological Momentary Assessment: how it is measured was reworded
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Start date Sep 1, 2026→Dec 1, 2026
    Primary completion Aug 31, 2029→Dec 31, 2029
    Study completion Nov 30, 2029→Jan 10, 2030
    Primary outcomes 4 time frame changed, 4 description edited
    What changed in the outcomes
    • Time frameAdapted Reverse CategorizationFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • Time frameZoo Animal SwitchFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • Time frameDevelopmental Profiles-4 Cognitive domainFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • Time frameDevelopmental Profiles-4 Social-emotional domainFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • DescriptionAdapted Reverse Categorization: how it is measured was reworded
    • DescriptionDevelopmental Profiles-4 Cognitive domain: how it is measured was reworded
    • DescriptionDevelopmental Profiles-4 Social-emotional domain: how it is measured was reworded
    • DescriptionZoo Animal Switch: how it is measured was reworded
    Secondary outcomes 6 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameiBehavior Ecological Momentary AssessmentFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • Time frameSelf ordered pointing: Garage GameFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • Time frameBRIEF-Preschool Inhibition DomainFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • Time frameHearts and FlowersFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • Time frameDevelopmental Profiles-4 Adaptive Behavior domainFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • Time frameBuilding TaskFrom enrollment to the end of treatment, with a 3-month follow-up → From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
    • DescriptioniBehavior Ecological Momentary Assessment: how it is measured was reworded
    + 3 other changes: verification date, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07792382
Responsible party
Sponsor
First posted
Aug 28, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Jan 10, 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

Kaylyn Van Deusen, MS
Contact
kaylyn.van_deusen@colostate.edu
9704911969
Miranda Pinks, MS
Contact
miranda.pinks@colostate.edu
970-4911969
Deborah Fidler
principal investigator · Colorado State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion